News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Actelion Ltd. (SW:ATLN) Initiates Phase IIb/III Program With Clazosentan



10/19/2005 5:08:49 PM

ALLSCHWIL, Switzerland, Dec. 22, 2004 (PRIMEZONE) -- Actelion Ltd (Other OTC:ALIOF) (SWX:ATLN) announced today it has initiated the comprehensive global Phase IIb/III development program for clazosentan, an intravenous endothelin receptor antagonist. This follows the completion of discussions with regulatory authorities in both the US and the European Union on all aspects of the clinical program, including clinical efficacy endpoints.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES